Results 191 to 200 of about 22,552 (237)
Some of the next articles are maybe not open access.
Cofactor of the “Lupus Anticoagulant”
Thrombosis and Haemostasis, 1974SummaryNormal plasma contains an activity known as cofactor which further lengthens the clotting time of the plasma of some patients with the “lupus anticoagulant.55 Cofactor has been characterized as either prothrombin or a gamma globulin. Our findings indicate that cofactor has the following properties: stable at room temperature but largely ...
G E, Rivard, S, Schiffman, S I, Rapaport
openaire +2 more sources
Lupus anticoagulants in children
Current Opinion in Hematology, 2003Lupus anticoagulant and ACAs are made up of heterogeneous IgG and IgM antibodies that prolong in vitro clotting times and are associated with increased risks of venous and arterial thrombosis, recurrent fetal loss, and autoimmune thrombocytopenia and anemia.
Michael, Briones, Thomas, Abshire
openaire +2 more sources
Lupus anticoagulant in myelofibrosis
The American Journal of the Medical Sciences, 1976A patient with myelofibrosis who also demonstrates a lupus anticoagulant is reported. The presence of a circulating anticoagulant adds to the list of potential hemorrhagic diatheses in myelofibrosis and also demonstrates myelofibrosis to involve a system that may be separate from the myeloid elements of the bone marrow.
B, Bernhardt, M, Valletta
openaire +2 more sources
2013
Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus ...
Karen, Moffat +2 more
openaire +2 more sources
Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus ...
Karen, Moffat +2 more
openaire +2 more sources
Neurology and the Lupus Anticoagulant
European Neurology, 2008The lupus anticoagulant, an immunoglobulin of the IgG or IgM class, is one of a group of antiphospholipid antibodies. Although an anticoagulant in vitro, its action in vivo is that of a procoagulant. This procoagulant activity may involve many organ systems including the nervous system.
H, Englert, G, Derue, G R, Hughes
openaire +2 more sources
British Journal of Haematology, 1987
SummaryThree families having more than one affected member with SLE or lupus‐like disease were investigated by global coagulation tests as well as methods based on dilute thromboplastin, Russell's viper venom and thermal stability/absorption, and by RIA for anticardiolipin (CL) antibodies. Of the 19 persons, 11 had SLE or lupus‐like disease.
I J, Mackie, C B, Colaco, S J, Machin
openaire +2 more sources
SummaryThree families having more than one affected member with SLE or lupus‐like disease were investigated by global coagulation tests as well as methods based on dilute thromboplastin, Russell's viper venom and thermal stability/absorption, and by RIA for anticardiolipin (CL) antibodies. Of the 19 persons, 11 had SLE or lupus‐like disease.
I J, Mackie, C B, Colaco, S J, Machin
openaire +2 more sources
Screening for the lupus anticoagulant
La Ricerca in Clinica e in Laboratorio, 1989The lupus anticoagulant may be defined as an immunoglobulin (IgG, IgM or both) which interferes with one or more of the in vitro phospholipid-dependent tests of coagulation. For many years, lupus anticoagulants were regarded as a laboratory nuisance; consequently, reagents were often selected on the basis of insensitivity to lupus anticoagulants ...
openaire +2 more sources
Rinsho byori. The Japanese journal of clinical pathology, 1993
Lupus anticoagulant (LAC) is an acquired inhibitor of prothrombin activator complex, which probably interferes with the phospholipid portion. Characteristically, LAC prolongs the partial prothrombin time, but only slightly prolongs the prothrombin time. It is a paradoxical fact that LAC is characterized by thrombosis.
A, Yoshida, K, Morozumi
openaire +1 more source
Lupus anticoagulant (LAC) is an acquired inhibitor of prothrombin activator complex, which probably interferes with the phospholipid portion. Characteristically, LAC prolongs the partial prothrombin time, but only slightly prolongs the prothrombin time. It is a paradoxical fact that LAC is characterized by thrombosis.
A, Yoshida, K, Morozumi
openaire +1 more source
"LUPUS" ANTICOAGULANT AND PROSTACYCLIN
The Lancet, 1981L O, Carreras, J, Vermylen
openaire +2 more sources